Literature DB >> 8384823

Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5.

M Kulka1, M Wachsman, S Miura, R Fishelevich, P S Miller, P O Ts'o, L Aurelian.   

Abstract

We have previously shown that an oligo(nucleoside methylphosphonate) (deoxynucleoside methylphosphonate residues in italics) complementary to the acceptor splice junction of herpes simplex virus type 1 (HSV-1) immediate-early (IE) pre-mRNAs 4,5 [d(TpTCCTCCTGCGG)], causes sequence-specific inhibition of virus growth in infected cell cultures (Smith et al., 1986; Kulka et al., 1989). Here we report a similar inhibition of HSV-1 growth by oligo(nucleoside methylphosphonates) complementary to the splice donor site of HSV-1 IE pre-mRNAs 4,5 [d(GpCTTACCCGTGC)] and to the translation initiation site of IE4 mRNA [d(ApATGTCGGCCAT)]. An oligomer complementary to the translation initiation site of IE5 mRNA [d(GpGCCCACGACAT)] or an unrelated oligomer [d(GpCGGGAAGGCAC)] did not inhibit virus growth. IC50 values were 20, 25 and 20 microM for d(TpTCCTCCTGCGG), d(GpCTTACCCGTGC) and d(ApATGTCGGCCAT) respectively. In infected BALB/c mice d(TpTCCTCCTGCGG) caused a significant decrease in HSV-1 growth (82% inhibition at 500 microM). A psoralen-derivative of d(TpTCCTCCTGCGG) that binds covalently to complementary sequences after exposure to 365 nm irradiation, inhibited HSV-1 growth (86-91%) at a 10-fold lower concentration than the non-derivatized oligomer. The inhibition was sequence-specific and significantly lower (27%) for HSV-2 that differs from HSV-1 in 7 of the 12 bases targeted by d(TpTCCTCCTGCGG). Virus growth was not inhibited by d(GpGCCCACGACAT). The data suggest that oligo(nucleoside methylphosphonates) may be effective antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384823     DOI: 10.1016/0166-3542(93)90002-z

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1.

Authors:  M Kulka; C C Smith; J Levis; R Fishelevich; J C Hunter; C D Cushman; P S Miller; P O Ts'o; L Aurelian
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

2.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.

Authors:  J Soul-Lawton; E Seaber; N On; R Wootton; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

3.  A herpes simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivo.

Authors:  K L Poffenberger; A D Idowu; E B Fraser-Smith; P E Raichlen; R C Herman
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 4.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.